A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients "IMPALA"

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients "IMPALA"

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Molgramostim (Primary)
  • Indications Pulmonary alveolar proteinosis
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPALA
  • Sponsors Savara Pharmaceuticals; Serendex Pharmaceuticals
  • Most Recent Events

    • 05 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Apr 2019.
    • 05 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Oct 2018.
    • 19 Aug 2017 Planned number of patients changed from 51 to 90.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top